Page last updated: 2024-08-24

nelfinavir and bortezomib

nelfinavir has been researched along with bortezomib in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	12 (85.71)	24.3611
2020's	2 (14.29)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Bruning, A; Burges, A; Friese, K; Mylonas, I; Vogel, M	1
Apcher, S; Arnulf, B; Bono, C; Bories, JC; Fermand, JP; Galicier, L; Harel, S; Karlin, L; Labaume, S; Mouly, E; Sauvageon, H	1
Dennis, PA; Gills, JJ; Hollander, MC; Kawabata, S; Lopiccolo, J; Mercado-Matos, JR; Wilson, W	1
Dorr, RT; Escalante, AM; Karolak, MR; Landowski, TH; Lynch, RM; McGrath, RT	1
Brüning, A; Friese, K; Rahmeh, M	1
Bader, J; Berset, C; Berthod, G; Driessen, C; Hawle, H; Hess, D; Hitz, F; Huitema, A; Joerger, M; Kraus, M; Mey, UJ; Overkleeft, HS; Pabst, T; Rosing, H; Sessa, C; von Moos, R; Xyrafas, A	1
Bader, J; Besse, A; Besse, L; Driessen, C; Kraus, M; Morgan, GJ; Overkleeft, HS; Rasche, L; Stolze, SC; Weinhold, N	1
Davies, DM; Dunlop, EA; Errington, RJ; Giles, PJ; Hay, T; Johnson, CE; Jones, AT; McCann, HD; Parfitt, GJ; Sampson, JR; Seifan, S; Shen, MH; Tee, AR	1
Berset, C; Besse, A; Besse, L; Betticher, D; Cantoni, N; Driessen, C; Hawle, H; Hitz, F; Mach, N; Mey, U; Müller, R; Novak, U; Pabst, T; Ribi, K; Rondeau, S; Rüfer, A; Samaras, P; Zander, T	1
Besse, A; Besse, L; Driessen, C; Kraus, M; Tarantino, I	1

Reviews

1 review(s) available for nelfinavir and bortezomib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for nelfinavir and bortezomib

Article	Year
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica, 2016, Volume: 101, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Leukemia; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Treatment Outcome; Unfolded Protein Response	2016
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood, 2018, 11-08, Volume: 132, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Inhibitors; Treatment Outcome	2018

Article

Year

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Haematologica, 2016, Volume: 101, Issue:3

Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Leukemia; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Treatment Outcome; Unfolded Protein Response

2016

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.

Blood, 2018, 11-08, Volume: 132, Issue:19

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Inhibitors; Treatment Outcome

2018

Other Studies

11 other study(ies) available for nelfinavir and bortezomib

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Current cancer drug targets, 2011, Volume: 11, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Drug Synergism; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Nelfinavir; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Uterine Cervical Neoplasms	2011
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica, 2012, Volume: 97, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Genes, Reporter; Histone Deacetylase Inhibitors; HIV Protease Inhibitors; Humans; Luciferases; Mice; Multiple Myeloma; Nelfinavir; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays	2012
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell death & disease, 2012, Jul-19, Volume: 3 Topics: Activating Transcription Factor 3; Animals; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Nude; Multiple Myeloma; Nelfinavir; Protease Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous	2012
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calpain; Cell Line, Tumor; Cell Survival; Drug Synergism; HIV Protease Inhibitors; Humans; Mice; Mice, SCID; Multiple Myeloma; Nelfinavir; Pyrazines; RNA, Small Interfering; Xenograft Model Antitumor Assays	2013
Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation. Molecular oncology, 2013, Volume: 7, Issue:6 Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; HIV Protease Inhibitors; Humans; Nelfinavir; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Pyrazines; TOR Serine-Threonine Kinases; Up-Regulation	2013
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia, 2018, Volume: 32, Issue:2 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HIV Protease Inhibitors; Humans; Lopinavir; Multiple Myeloma; Nelfinavir; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors	2018
Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene, 2018, Volume: 37, Issue:45 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Nelfinavir; Neoplasms; Tuberous Sclerosis Complex 2 Protein; Xenograft Model Antitumor Assays	2018
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. Scientific reports, 2023, 03-17, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Proteasome Inhibitors	2023